Skip to search formSkip to main contentSkip to account menu

FRA9E gene

Known as: FRA9E, fragile site, aphidicolin type, common, fra(9)(q32) 
National Institutes of Health

Related topics

Related topics

1 relation
FRA10A gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
2′-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2′-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile…
5-Aza-2′-deoxycytidine (5azaC-dR) has been employed as an inhibitor of DNA methylation, a chemotherapeutic agent, a clastogen, a… 
Review
2008
Review
2008
Human chromosome fragility.
2007
2007
Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
FRA2G chr2: 169,452,095170,292,618 RH91148 RH1293 5 1 1 FRA3B chr3: 59,594,24164,182,258 D3S3577 D3S1287 6 1 FRA4F chr4: 89,694… 
Highly Cited
2003
Highly Cited
2003
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer
Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The… 
Review
2003
Review
2003
Fragile sites and bladder cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License